Exelixis Inc
NASDAQ:EXEL

Watchlist Manager
Exelixis Inc Logo
Exelixis Inc
NASDAQ:EXEL
Watchlist
Price: 35.61 USD 2.24% Market Closed
Market Cap: 10.2B USD
Have any thoughts about
Exelixis Inc?
Write Note

Exelixis Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Exelixis Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Exelixis Inc
NASDAQ:EXEL
Pre-Tax Income
$599.9m
CAGR 3-Years
43%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$7.2B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$176m
CAGR 3-Years
-73%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.7B
CAGR 3-Years
-10%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$259.6m
CAGR 3-Years
-54%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5B
CAGR 3-Years
-15%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Exelixis Inc
Glance View

Market Cap
10.2B USD
Industry
Biotechnology

Exelixis Inc., a prominent player in the biotech landscape, is dedicated to advancing cancer treatment through its innovative drug development programs. Founded in 1994 and based in South San Francisco, the company made its mark with cabozantinib, a multi-kinase inhibitor that targets key pathways involved in tumor growth, particularly in advanced kidney and liver cancers. Since its initial approval in 2012, cabozantinib has not only become a cornerstone of Exelixis's product portfolio but has also garnered recognition for improving patient outcomes where traditional therapies have fallen short. This success has positioned Exelixis as a leader in precision medicine, with a robust pipeline that includes additional therapies currently undergoing clinical trials, aimed at expanding treatment options for various cancer types. For investors, Exelixis offers an appealing blend of established market presence and promising growth potential. The company's strategic focus on maximizing cabozantinib’s sales while developing complementary therapies ensures a sustainable revenue stream, which is further supported by collaborations with major pharmaceutical partners. As the company continues to explore new indications and combinations, it signals a commitment to innovation that could enhance shareholder value. Moreover, Exelixis operates in a rapidly evolving market characterized by increasing demand for targeted cancer therapies, positioning itself well to capitalize on future opportunities. With a solid foundation and a forward-looking approach, Exelixis Inc. stands out as a compelling investment choice for those looking to participate in the biotech sector's growth.

EXEL Intrinsic Value
25.99 USD
Overvaluation 27%
Intrinsic Value
Price

See Also

What is Exelixis Inc's Pre-Tax Income?
Pre-Tax Income
599.9m USD

Based on the financial report for Sep 30, 2024, Exelixis Inc's Pre-Tax Income amounts to 599.9m USD.

What is Exelixis Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
7%

Over the last year, the Pre-Tax Income growth was 387%. The average annual Pre-Tax Income growth rates for Exelixis Inc have been 43% over the past three years , 7% over the past five years .

Back to Top